Neurovie® 100 Units

Clostridium Botulinum Neurotoxin Type A

NEUROVIE® 100U — is...

- Highly purified botulinum toxin type A by Meamo Labs, developed for aesthetic medicine professionals focused on stability, clinical reproducibility, and predictable outcomes
- The production of Neurovie® complies with current pharmaceutical standards for quality control and biological activity
- Neurovie® 100U contains purified botulinum toxin type A derived from Clostridium botulinum
- Neurovie® 100U is supplied as a lyophilized powder in a 100-unit vial for subsequent reconstitution with sterile 0.9% sodium chloride solution

PURITY
YOU CAN TRUST
RESULTS
YOU CAN PREDICT

INDICATIONS FOR USE

Neurovie® 100U

Neurovie® 100U is indicated for temporary correction of moderate to severe dynamic facial wrinkles, including:

vertical glabellar lines

lateral periorbital lines

horizontal forehead lines

MECHANISM OF ACTION

- Botulinum toxin type A temporarily blocks the release of acetylcholine at the neuromuscular junction, resulting in a reversible reduction of muscle activity
- Controlled relaxation of the targeted facial muscles leads to a visible reduction in dynamic wrinkles while preserving natural facial expression

CLINICAL DATA

STUDY RESULTS

The efficacy and safety of botulinum toxin type A manufactured using this pharmaceutical technological platform were evaluated in a multicenter, double-blind, randomized, active-controlled Phase III clinical trial in patients with moderate to severe glabellar lines

- The safety profile was comparable to that of the active control product
- Non-inferiority analysis confirmed comparable clinical efficacy
- The duration of the clinical effect is consistent with that typically observed for botulinum toxin type A products and averages 4–6 months

- Clinical improvement in the severity of glabellar lines at 4 weeks was observed

IN 78,83% OF PATIENTS

AND 83,09% OF PATIENTS IN THE CONTROL GROUP

PHARMACEUTICAL-GRADE MANUFACTURING STANDARDS

Neurovie® is manufactured at a certified facility in South Korea in compliance with the requirements of the Ministry of Food and Drug Safety (MFDS) applicable to botulinum toxin type A products. The manufacturing cycle includes multi-level quality control at every stage — from cultivation to final batch release

HIGH PURITY LEVEL

- Analysis of toxic protein purity is performed in accordance with international standards using the SEC-HPLC (Size-Exclusion High Performance Liquid Chromatography). The average purity level is 99.5%, reflecting a high degree of removal of accessory protein components



CONTROLLED BIOLOGICAL ACTIVITY

- Biological activity is controlled in accordance with the requirements of the European Pharmacopoeia. Within the reference range of 80–125%, 80–125%, the average batch potency is 112,3%, demonstrating the stability of the manufacturing process and reproducibility of performance parameters



TECHNOLOGY FOCUSED ON STABILITY

LOW-TEMPERATURE VACUUM DRYING (9–15 °C)

- Controlled lyophilization **minimizes thermal exposure and helps preserve the structural integrity** of the protein molecule

CONTROL OF CRITICAL ENVIRONMENTAL PARAMETERS

- Monitoring of temperature and process parameters is aimed at ensuring the stability of **Neurovie®** and the reproducibility of characteristics across each batch

DOSAGE AND ADMINISTRATION

Neurovie® 100U

Injections of Neurovie® 100U should be performed by qualified medical professionals clinical practice

RECONSTITUTION

- Neurovie® 100U is supplied in 100-unit vials in lyophilized form and is reconstituted with sterile 0.9% isotonic sodium chloride solution.

  In clinical practice, a 2.5 mL dilution is commonly used, resulting in a concentration of 4 units per 0.1 mL

DOSAGE AND ADMINISTRATION

- Dosage is determined individually based on the treatment area, the severity of facial muscle activity, and the patient's anatomical characteristics. Suggested dosing guidelines do not replace the clinical judgment of the treating specialist

POST-PROCEDURE RECOMMENDATIONS

- During the first 24 hours after injection, patients are advised to avoid facial massage, heat exposure, intense physical activity, and alcohol consumption

ONSET OF EFFECT

- Initial changes may be observed within the first 24 hours after administration. Full development of the clinical effect is typically noted within several weeks and depends on the individual characteristics of the patient and the injection technique

SAFETY PROFILE

REACTIONS

The most commonly reported reactions typical of botulinum toxin type A products include:

- local tenderness
- erythema
- swelling
- headache
- temporary asymmetry or ptosis (rare)

THE SAFETY PROFILE OF NEUROVIE® IN THE CLINICAL TRIAL WAS COMPARABLE TO THAT OF THE ACTIVE CONTROL PRODUCT

PRESENTATION

Vial containing 100 units of botulinum toxin type A in lyophilized form

CONTRAINDICATIONS

Neurovie® is contraindicated in cases of:

- hypersensitivity to any components of the product
- myasthenia gravis, Lambert–Eaton syndrome, and other disorders of neuromuscular transmission
- presence of infection or inflammation at the intended injection site
- pregnancy and breastfeeding (in the absence of sufficient clinical data)

STORAGE CONDITIONS

- Storage temperature: 2–8 °C (36–46°F)
- Shelf life of an unopened vial: 36 months
- The reconstituted product is recommended to be used within 24 hours when stored under refrigeration

IMPORTANT INFORMATION

Neurovie® 100U is intended for use **by qualified medical professionals only.**

Before use, **the Instructions for Use (IFU)** should be carefully reviewed

CLINICAL EXAMPLES

clinical example №01

* Patient before-and-after photographs are presented in accordance with clinical protocols. Individual results may vary

PHYSICIAN'S COMMENTARY

- The treatment protocol was aimed at reducing hyperactivity of the targeted muscles while maintaining natural facial expression. The clinical response was consistent with the expected action profile of botulinum toxin type A

- Patient: 29 years old
- Treatment areas: glabellar region, masseter muscles

BASELINE CLINICAL PRESENTATION

- pronounced activity of the corrugator and procerus muscles at rest and during facial expression
- hypertonicity of the masseter muscles
- visible heaviness of the lower third of the face
- subjective complaints of persistent muscle tension

before

POST-TREATMENT RESULTS

- reduced activity of the glabellar facial musculature
- controlled relaxation of the masseter muscles
- softening of the contours of the lower third of the face
- decrease in the subjective sensation of muscle tension

after

- The result demonstrates predictable muscle relaxation while preserving natural facial dynamics

NEUROVIE® 100U —

STANDARDIZED PURITY

CONTROLLED BIOLOGICAL ACTIVITY

CLINICAL REPRODUCIBILITY

MEAMO LABS

WEB	WWW.MEAMO.SPACE
EMAIL	INFO@MEAMO.CO
INST	@MEAMOLAB
TEL	+82 (70) 4513-1496